September 2012 | Oncology & Biotech News

October 19, 2012

Founded in 1913 as a tuberculosis sanatorium, City of Hope today enjoys a reputation as a leading research, treatment, and education center for those with cancer, diabetes, and other life-threatening diseases.

October 18, 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

October 17, 2012

Patients 75 years of age or older with stage III colon cancer may expect a survival benefit from adjuvant chemotherapy that rivals that previously reported in younger patients.

October 17, 2012

Integrative model unites physicians, hospitals, and payers to deliver evidence-based care and control cancer costs.

October 10, 2012

The addition of aprepitant to standard antiemetic prophylaxis significantly improved the complete response rate in patients with germ cell tumors undergoing 5-day cisplatin combination chemotherapy regimens.

October 10, 2012

Nearly 2 years after a landmark study supported CT for people at high risk of developing lung cancer, questions persist about the complexities of implementing an early detection program.

October 09, 2012

The addition of sorafenib to first-line gemcitabine/cisplatin does not appear to lengthen survival in patients with advanced, nonsquamous, non–small cell lung cancer.

October 09, 2012

Driven by changes in reimbursement and standards of care, independent community oncology practices continue to dwindle.

October 08, 2012

Dose-dense induction with high-dose chemotherapy/autologous stem-cell transplantation is reasonable for use as first-line treatment of transplantation-eligible patients with systemic peripheral T-cell lymphomas.

October 05, 2012

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.

October 05, 2012

During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.

September 27, 2012

Decitabine produced a higher response rate than standard therapies in older patients with newly diagnosed acute myeloid leukemia without major differences in safety.

September 26, 2012

A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.

September 26, 2012

Pretreatment serum lactate dehydrogenase is a prognostic factor in poor-risk patients with renal cell carcinoma and also a predictive factor for a survival benefit from treatment with temsirolimus.

September 25, 2012

A consortium of over 442 global investigators at 32 institutions recently reported results in over 30 publications of a decade of work from the Encyclopedia of DNA Elements project.